Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva stops selling generic Univasc

Executive Summary

Teva has ceased its "at-risk" launch of a generic version of Schwarz' ACE-inhibitor Univasc. The company said the decision was part of an agreement with Schwarz. "Under the terms of the agreement, Teva will suspend all manufacturing and selling of its moexipril HCl tablets pending the outcome of litigation between the two companies in the U.S. District Court for the District of New Jersey or an order of the court," a Sept. 13 1Teva press release said. A 2Schwarz press release issued Sept. 14 emphasizes there has been no settlement in the case and states, "We believe the action by Teva to remove its product from the market reflects the strength of Schwarz Pharma's patent infringement case against them, and we will continue to aggressively seek damages." Schwarz said that after Teva's announcement, which came the day a hearing on a preliminary injunction had been scheduled, the district court enjoined Teva from selling the generic. Teva launched moexipril at-risk in May 2003 following a district court decision that it did not infringe Schwarz' patent. In January, an appeals court vacated the decision, but Teva said it would continue marketing (3"The Pink Sheet" Feb. 2, 2004, In Brief)...

You may also be interested in...

Teva moexipril decision

Teva plans to continue distribution of the antihypertensive agent moexipril following decision by a federal court of appeals to overturn a March 2003 New Jersey district court's summary judgement, which found that Teva did not infringe Schwarz' moexipril patent (no. 4,742,450). Teva began selling moexipril in May 2003, immediately following its May 8 approval. Schwarz licensed rights to Univasc (moexipril) from Warner-Lambert (now Pfizer)...

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head

Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts